Lower riskDrug recall · FDA · Published October 18, 2022
Genentech Susvimo Ocular Implant Recall: Defective Delivery System Risk
Genentech recalls Susvimo (ranibizumab injection) due to defective delivery system causing implants to become non-functional. Affected lots expire by 2027.
Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.
Take action
Contact the company
📍Recalling firmGenentech Inc1 Dna Way · South San Francisco, CA 94080-4918
“Genentech Susvimo Ocular Implant Recall: Defective Delivery System Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34237-genentech-susvimo-ocular-implant-recall-defective-delivery-system-risk. Based on FDA recall #D-0025-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0025-2023%22&limit=1).
The FDA announced on Oct. 18, 2022, that Genentech Inc. is recalling Susvimo (ranibizumab injection) due to a defective delivery system that may render the implant non-functioning. The agency classified the Class III recall as voluntary.
According to the FDA, commercial implants do not meet the filed specification for intended use. A few patients have experienced an issue with the implants that renders it non-functioning.
Context
GovInfoNow's records show Genentech, Inc. has 9 other recalls on record since 2012-07-30. Other recent recalls of similar products include Genentech Cathflo Activase 2mg Vials Recall (2024-05-20), Genentech Xolair 150mg Injection Recall (2021-06-09), and Genentech Evrysdi Oral Solution Recall (2021-04-20). Other recent recalls of similar products include Wizcure Pharmaa Eye Drops Recall (2025-12-31), Accord IMULDOSA Injection Recall (2026-06-10), and Opdualag Injection Recall (2025-10-21).
How to tell if you have this one
Check the lot number on the Susvimo carton. Recalled lots include: 3499188 (exp 10/31/2022), 3523071 (exp 6/30/2023), and several others expiring through 2027.
Brand
Genentech
Product
Genentech Inc recalls Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Lot Number
Look for the lot number on the Susvimo carton to determine if it's in the recalled list.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 18 months after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0025-2023 (October 18, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0025-2023 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.